GET DAILY SIGNALSAptarGroup (ATR) Delivers Q3 Earnings Beat Despite One-Time Hits
Key Takeaways
- AptarGroup reported third quarter 2026 adjusted earnings per share (EPS) of $1.52, beating the analyst consensus estimate of $1.47 by $0.05.
- Revenue came in at approximately $1.02 billion, topping consensus expectations of roughly $981 million and rising about 6% year over year.
- Reported (GAAP) diluted EPS fell sharply to $0.51, weighed down by a $58 million loss tied to the Russia deconsolidation and non-ordinary-course litigation costs.
- The company issued fourth quarter 2026 adjusted EPS guidance of $1.39 to $1.47, bracketing the analyst consensus of $1.41.
- Growth was broad-based across all three segments — Pharma, Beauty, and Closures — with double-digit core sales growth in Closures.
- For deeper context, explore AptarGroup's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- You can also discover market-moving signals and automated strategies through Tickeron's Trending AI Robots.
Why These Results Matter
AptarGroup sits at the intersection of healthcare and consumer packaging, supplying drug delivery and dispensing technologies to pharmaceutical, beauty, and food-and-beverage customers globally. The third-quarter report therefore provides a useful window into prescription drug demand, new product activity in injectables and central nervous system therapies, and broader consumer spending trends. It also represents the first full quarter under new CEO Gael Touya, so the tone of management commentary and the forward guidance drew particular attention. The sizable gap between adjusted and GAAP earnings underscores how one-time items, such as the Russia deconsolidation loss and litigation costs, can obscure underlying operational performance even when core sales continue to expand.
Breaking Down the Quarter
AptarGroup posted third quarter 2026 revenue of roughly $1.02 billion, up about 6% from $961.1 million a year earlier and ahead of the consensus estimate near $981 million. Adjusted EPS of $1.52 cleared the $1.47 consensus, reflecting solid operational results across the three segments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
On a GAAP basis the picture looked weaker. Diluted EPS fell to $0.51, a decline of about 73% year over year, while net income attributable to common shareholders dropped to roughly $32.6 million. The main drivers were a $58 million loss on the Russia deconsolidation and other special items tied to non-ordinary-course litigation, including the ongoing disputes with ARS Pharmaceuticals over trade-secret claims.
Operating income eased 1.4% to $135.0 million, while gross profit rose 2.7% to $372.9 million. Management guided fourth quarter 2026 adjusted EPS to a range of $1.39 to $1.47, which brackets the analyst consensus of $1.41.
Market Reaction
Investor sentiment appeared to reflect the contrast between clean top-line and adjusted-EPS beats and a noisier GAAP result. The revenue and adjusted-earnings outperformance pointed to healthy underlying demand, especially in pharma and beverage-dispensing innovation, while the Russia charge and litigation costs raised questions about earnings quality. Fourth-quarter guidance landed roughly in line with expectations, offering neither a strong catalyst nor a clear negative surprise. Pre-report sentiment had been cautious, and the mixed headline numbers left the market balancing operational momentum against the impact of non-recurring items.
Forward Outlook
Investors will want to track whether AptarGroup can maintain momentum in the Pharma segment, which showed notable growth in central nervous system therapies, pulmonary treatments, injectables, and consumer healthcare. Management continues to stress converting its pharma pipeline into commercial launches, and the pace of those conversions should remain a key driver.
The Closures segment also merits attention after delivering double-digit core sales growth fueled by beverage-dispensing innovation. Sustaining that pace will hinge on customer adoption and further product rollouts.
Cost discipline and margin trends are additional points to watch. Although gross profit expanded, operating income dipped slightly, so investors will look for one-time litigation and deconsolidation items to fade in coming quarters.
Finally, under new CEO Gael Touya, attention will turn to any shifts in capital allocation and execution priorities, including the focus on deeper customer relationships, faster innovation, and greater consistency that could influence both organic growth and potential acquisitions.
Using AI Tools in My Analysis
When evaluating companies like ATR, I often turn to Tickeron’s AI Screener to quickly compare fundamentals, technical patterns, and peer performance across the packaging and pharma supply space. It helps surface relevant setups without spending hours on manual filtering, which keeps my research process efficient.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ATR in +3.26% Uptrend, rising for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ATR advanced for three days, in 181 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on ATR as a result. In 41 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 50%.
The Moving Average Convergence Divergence (MACD) for ATR just turned positive on October 14, 2026. Looking at past instances where ATR's MACD turned positive, the stock continued to rise in 31 of 58 cases over the following month. The odds of a continued upward trend are 53%.
ATR moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ATR crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for ATR moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
ATR broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ATR entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 39 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating steady price growth. ATR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.160) is normal, around the industry mean (5.000). P/E Ratio (23.329) is within average values for comparable stocks, (37.535). Projected Growth (PEG Ratio) (2.595) is also within normal values, averaging (4.143). Dividend Yield (0.015) settles around the average of (0.005) among similar stocks. P/S Ratio (2.072) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 80 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of consumer dispensing systems
Industry PharmaceuticalsOther
Advertisement